The most emetogenic anticancer drug is :
**Core Concept**
Chemotherapy-induced nausea and vomiting (CINV) is a major side effect of cancer treatment, with some anticancer drugs being more emetogenic than others. The etiology of CINV involves the activation of the vomiting centers in the brain, which are triggered by the release of neurotransmitters such as dopamine, acetylcholine, and serotonin.
**Why the Correct Answer is Right**
The correct answer is **Doxorubicin**, a anthracycline antibiotic that is widely used in the treatment of various cancers. Doxorubicin is known to be one of the most emetogenic anticancer drugs due to its ability to stimulate the release of serotonin from the enterochromaffin cells in the gastrointestinal tract, which then activates the vomiting centers in the brain. This leads to a rapid and intense emetic response. The emetogenic potential of doxorubicin is thought to be mediated through its interaction with the serotonin receptors in the brain, particularly the 5-HT3 receptors.
**Why Each Wrong Option is Incorrect**
**Option A:** Cyclophosphamide is another chemotherapeutic agent that can cause nausea and vomiting, but it is not as emetogenic as doxorubicin. Cyclophosphamide is metabolized to acrolein, which is responsible for its emetogenic effects.
**Option B:** Carboplatin is a platinum-based chemotherapeutic agent that can cause nephrotoxicity and ototoxicity, but it is not as emetogenic as doxorubicin. Carboplatin's emetogenic potential is thought to be mediated through its interaction with the dopamine receptors in the brain.
**Option C:** Etoposide is a topoisomerase inhibitor that is used in the treatment of various cancers, including testicular cancer and lung cancer. While etoposide can cause nausea and vomiting, it is not as emetogenic as doxorubicin.
**Clinical Pearl / High-Yield Fact**
To minimize the risk of CINV, it is essential to use antiemetic prophylaxis in patients receiving emetogenic chemotherapy, such as doxorubicin. The 5-HT3 receptor antagonists, such as ondansetron, are effective in preventing CINV in patients receiving doxorubicin.
**Correct Answer:** D. Doxorubicin.